Data on Albireo’s Odevixibat Presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
07 juin 2019 07h00 HE
|
Albireo Pharma, Inc.
BOSTON, June 07, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that clinical...
Albireo to Present at Investor Conferences in June
29 mai 2019 07h30 HE
|
Albireo Pharma, Inc.
BOSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting
23 mai 2019 07h30 HE
|
Albireo Pharma, Inc.
BOSTON, May 23, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
Albireo Reports First Quarter 2019 Financial Results
09 mai 2019 07h30 HE
|
Albireo Pharma, Inc.
Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as plannedInitiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announcedOdevixibat pivotal trial in biliary atresia...
Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
02 mai 2019 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019
13 avr. 2019 07h30 HE
|
Albireo Pharma, Inc.
- Reduction in serum bile acids and pruritus observed in both populations – - Alagille abstract selected for inclusion in ’Best of ILC’ – - Albireo plans to initiate second A4250 pivotal program in...
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
11 avr. 2019 07h30 HE
|
Albireo Pharma, Inc.
– Initiation of Phase 2 clinical trial expected in Q2 2019 – – IBAT inhibition has potential to impact key markers of NASH – BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:...
Albireo to Present at Investor Conferences in April
01 avr. 2019 07h30 HE
|
Albireo Pharma, Inc.
BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced...
Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019
27 mars 2019 08h48 HE
|
Albireo Pharma, Inc.
BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
Albireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial Officer
21 mars 2019 08h30 HE
|
Albireo Pharma, Inc.
-- Significant recent rare disease product launch and access experience -- -- Key addition as Albireo prepares for commercialization of A4250 -- BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- Albireo...